株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙SALE
市場調査レポート

生物学的治療薬の世界市場:2015年〜2019年

Global Biologic Therapeutics Market 2015-2019

発行 TechNavio (Infiniti Research Ltd.) 商品コード 317801
出版日 ページ情報 英文 104 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.58円で換算しております。
SALE 2017年12月31日まで 期間限定キャンペーン
Back to Top
生物学的治療薬の世界市場:2015年〜2019年 Global Biologic Therapeutics Market 2015-2019
出版日: 2015年10月21日 ページ情報: 英文 104 Pages
概要

世界の生物学的治療薬市場は、2014年〜2019年のCAGRで、8.26%の成長が見込まれています。

当レポートでは、世界の生物学的治療薬市場について調査分析し、市場規模と成長率、市場動向、市場促進要因・課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

第1章 エグゼクティブサマリー

  • ハイライト

第2章 調査範囲

  • 市場概要
  • 主要ベンダー製品

第3章 市場調査手法

  • 調査手法
  • 経済指標

第4章 イントロダクション

  • 主要市場ハイライト

第5章 市場情勢

  • 市場概要
  • 市場規模と予測
  • ファイブフォース分析

第6章 市場区分:分子タイプ別

第7章 世界のタンパク質治療薬市場

  • イントロダクション
  • 促進要因、課題、動向
  • 市場区分:分子タイプ別

第8章 世界のワクチン市場

  • イントロダクション
  • 促進要因、課題、動向
  • 市場区分:エンドユーザー年齢層別

第9章 世界の細胞療法市場

  • イントロダクション
  • 促進要因、課題、動向
  • 市場規模と予測

第10章 地理区分

  • 南北アメリカ
  • 欧州・中東・アフリカ
  • アジア太平洋地域

第11章 市場促進要因

第12章 促進要因の影響

第13章 市場の課題

第14章 促進要因と課題の影響

第15章 市場動向

第16章 ベンダー情勢

  • 競合シナリオ
  • 市場シェア分析
  • その他の有力ベンダー

第17章 主要ベンダー分析

  • Amgen
  • F. Hoffmann-La Roche
  • Novo Nordisk
  • Sanofi

第18章 付録

第19章 Technavioについて

図表

図表
  • Exhibit 01: Product offerings
  • Exhibit 02: Global biologic therapeutics market 2014-2019 ($ millions)
  • Exhibit 03: Five forces analysis
  • Exhibit 04: Global biologic therapeutics market segmentation by type of molecules
  • Exhibit 05: Global biologic therapeutics market segmentation by type of molecules 2014
  • Exhibit 06: Global biologic therapeutics market segmentation by type of molecules 2014-2019 ($ billions)
  • Exhibit 07: Key drivers and challenges of global protein therapeutics market
  • Exhibit 08: Key trends of global protein therapeutics market
  • Exhibit 09: Global protein therapeutics market 2014-2019 ($ billions)
  • Exhibit 10: Global protein therapeutics market 2014
  • Exhibit 11: Global protein therapeutics market by type of molecules 2014-2019 ($ billions)
  • Exhibit 12: Global monoclonal antibodies market 2014-2019 ($ billions)
  • Exhibit 13: Global enzymes market 2014-2019 ($ billions)
  • Exhibit 14: Global other protein therapeutics market 2014-2019 ($ billions)
  • Exhibit 15: Drivers of global vaccines market
  • Exhibit 16: Challenges of global vaccines market
  • Exhibit 17: Trends in global vaccines market
  • Exhibit 18: Global vaccines market 2014-2019 ($ billions)
  • Exhibit 19: Global vaccines market by end-user age group 2014
  • Exhibit 20: Global vaccines market by end-user age group 2014-2019 ($ billions)
  • Exhibit 21: Global pediatric vaccines market 2014-2019 ($ billions)
  • Exhibit 22: Global adult vaccines market 2014-2019 ($ billions)
  • Exhibit 23: Key factors influencing the global cell therapy market
  • Exhibit 24: Global cell therapy market 2014-2019 ($ billions)
  • Exhibit 25: Global biologic therapeutics market by geography 2014
  • Exhibit 26: Biologic therapeutics market in Americas 2014-2019 ($ billions)
  • Exhibit 27: Biologic therapeutics market in EMEA 2014-2019 ($ billions)
  • Exhibit 28: Biologic therapeutics market in APAC 2014-2019 ($ billions)
  • Exhibit 29: Global biologic therapeutics market by geography 2014-2019 ($ billions)
  • Exhibit 30: Impact of drivers
  • Exhibit 31: Impact of drivers and challenges
  • Exhibit 32: Revenue of Enbrel 2012-2014 ($ millions)
  • Exhibit 33: Revenue of Epogen 2012-2014 ($ millions)
  • Exhibit 34: Revenue of Neulasta/Neupogen 2012-2014 ($ millions)
  • Exhibit 35: Revenue of vectibix 2012-2014 ($ millions)
  • Exhibit 36: Revenue of Xgeva 2012-2014 ($ millions)
  • Exhibit 37: Revenue of Prolia 2012-2014 ($ millions)
  • Exhibit 38: Revenue of Avastin 2012-2014 ($ millions)
  • Exhibit 39: Revenue of Kadcyla 2013 and 2014 ($ millions)
  • Exhibit 40: Revenue of Lucentis 2012-2014 ($ millions)
  • Exhibit 41: Revenue of Rituxan/MabThera 2012-2014 ($ millions)
  • Exhibit 42: Revenue of Pegasys 2012-2014 ($ millions)
  • Exhibit 43: Revenue of Perjeta 2013 and 2014 ($ millions)
  • Exhibit 44: Revenue of Pulmozyme 2012-2014 ($ millions)
  • Exhibit 45: Revenue of Pulmozyme 2012-2014 ($ millions)
  • Exhibit 46: Revenue of Apridra 2012-2014 ($ millions)
  • Exhibit 47: Revenue of Cerezyme 2012-2014 ($ millions)
  • Exhibit 48: Revenue of Fabrazyme 2012-2014 ($ millions)
  • Exhibit 49: Revenue of Myozyme/Lumizyme 2012-2014 ($ millions)
  • Exhibit 50: Revenue of Lantus 2012-2014 ($ millions)
  • Exhibit 51: Revenue of Zaltrap 2012-2014 ($ millions)
  • Exhibit 52: Amgen: Business segmentation by revenue 2014
  • Exhibit 53: Amgen: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 54: Amgen: Geographical segmentation by revenue 2014
  • Exhibit 55: Novo Nordisk: Business segmentation by revenue 2014
  • Exhibit 56: Novo Nordisk: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 57: Novo Nordisk: Geographical segmentation by revenue 2014
  • Exhibit 58: Novo Nordisk: R&D expenditure 2014
  • Exhibit 59: Business segmentation by revenue 2013 and 2014 ($ billions)

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: IRTNTR7720

About biologic therapeutics

Biologic therapeutics include virus, therapeutic serums, toxins, allergenic products, antitoxin, blood components or derivatives, vaccines, blood, and proteins (except any chemically synthesized polypeptide). They also include analogous products, arsphenamine, or derivatives of arsphenamine (or any other trivalent organic arsenic compound) for the prevention, treatment, or cure of a disease. The differences between the biologics and small molecules include the molecular weight, structure, procedure of synthesis, and immunogenicity. Biologics have a higher molecular weight and a complex molecular structure. They are usually derived from living entities, which is another important feature that differentiates it from small molecules. Biologics are also vulnerable to extreme temperatures (thermolabile) and light.

Technavio's analysts forecast the global biologic therapeutics market to grow at a CAGR of 8.26% over the period 2014-2019.

Covered in this report

This report covers the present scenario and the growth prospects of the global biologic therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sales protein therapeutics (monoclonal antibodies, enzymes, and other protein therapeutics).

Other protein therapeutics covers proteins such as cytokines, fusion proteins, peptide antibiotics, peptide hormones, and blood factors.

The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the market. The vendor landscape section includes a market share analysis of the major vendors along with the competitive performances of their product portfolios. In addition, the report discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends emerging in the market.

Technavio's report, Global Biologic Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global biologic therapeutics market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions

  • Americas
  • APAC
  • EMEA

Key vendors

  • Amgen
  • F. Hoffmann-La Roche
  • Novo Nordisk
  • Sanofi

Other Prominent Vendors

  • AbbVie
  • AstraZeneca
  • Bavarian Nordic
  • Baxter International
  • Beijing Minhai Biotechnology
  • Bharat Biotech
  • Bharat Immunologicals and Biologicals
  • Bio Med Pvt.
  • bioCSL
  • Biodel
  • Bristol-Myers Squibb
  • Diamyd Medical
  • DiaVacs
  • Dynavax Technologies
  • Eli Lilly
  • Generex Biotechnology
  • Hualan Biological Engineering
  • Imunoloski Zavod
  • Indian Immunologicals
  • Janssen
  • JN International Medical
  • Kaketsuken
  • LG Life Sciences
  • Macrogenics
  • MannKind
  • Merck
  • Mitsubishi Tanabe Pharma
  • Nuron Biotech
  • Osiris Therapeutics
  • Pfizer
  • Protalix
  • Protein Sciences
  • Serum Institute of India
  • Shenzhen Kangtai Biological Products
  • Sinovac Biotech
  • Tolerion
  • Vacunas Finlay
  • XOMA
  • Zydus Cadila

Market driver

  • Reimbursement support for biologics
  • For a full, detailed list, view our report

Market challenge

  • High cost of therapy
  • For a full, detailed list, view our report

Market trend

  • Emergence of targeted and combination therapies
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 06: Market segmentation by type of molecules

PART 07: Global protein therapeutics market

  • Introduction
  • Drivers, challenges, and trends
  • Market segmentation by type of molecules

PART 08: Global vaccines market

  • Introduction
  • Drivers, challenges, and trends
  • Market segmentation by end-user age group

PART 09: Global cell therapy market

  • Introduction
  • Drivers, challenges, and trends
  • Market size and forecast

PART 10: Geographical segmentation

  • Biologic therapeutics market in Americas
  • Biologic therapeutics market in EMEA
  • Biologic therapeutics market in APAC

PART 11: Market drivers

  • Reimbursement support for biologics
  • Promising drug pipeline
  • Focus on development of novel mechanisms
  • Increase in industry-academia collaborations

PART 12: Impact of drivers

PART 13: Market challenges

  • High cost of therapy
  • Stringent regulatory guidelines
  • Fierce market competition
  • Cold chain management
  • Poor diagnosis and screening

PART 14: Impact of drivers and challenges

PART 15: Market trends

  • Emergence of targeted and combination therapies
  • Increase in R&D
  • Shift in focus to untapped markets
  • Rise in public awareness

PART 16: Vendor landscape

  • Competitive scenario
  • Key news
  • Mergers and acquisitions
  • Market share analysis
  • Amgen
  • F. Hoffmann-La Roche
  • Novo Nordisk
  • Sanofi
  • Other and future prominent vendors

PART 17: Key vendor analysis

  • Amgen
  • F. Hoffmann-La Roche
  • Novo Nordisk
  • Sanofi

PART 18: Appendix

  • List of abbreviations

PART 19: Explore Technavio

Back to Top